Moreover, ongoing phase II-IV clinical trials such as PALINA, NCT02600923, NCT02679755 and NCT03633331 are exploring the most frequent adverse effects resulting from the application of Palbociclib in HR+/HER2- advanced breast cancer patients. Here, ERBB2 is linked to breast carcinoma.